Estats Units - anglès - NLM (National Library of Medicine)

redpharm drug, inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets, usp and other treatment options before deciding to use diclofenac sodium delayed-release tablets, usp. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). diclofenac sodium delayed-release tablets are indicated: for relief of the signs and symptoms of osteoarthritis for relief of the signs and symptoms of rheumatoid arthritis for acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis diclofenac sodium delayed-release tablets, usp are contraindicated in patients with known hypersensitivity to diclofenac. diclofenac sodium delayed-release should not be given to patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylactoid reac

Estats Units - anglès - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings; gastrointestinal bleeding, ulceration, and perforation) . diclofenac sodium delayed-release tablets, usp are indicated: - for relief of the signs and symptoms of osteoarthritis - for relief of the signs and symptoms of rheumatoid arthritis - for acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis diclofenac sodium delayed-release tablets are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see warnings; anaphylactic reactions, serious skin reaction

Estats Units - anglès - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings; gastrointestinal bleeding, ulceration, and perforation) . diclofenac sodium delayed-release tablets, usp are indicated: - for relief of the signs and symptoms of osteoarthritis - for relief of the signs and symptoms of rheumatoid arthritis - for acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis diclofenac sodium delayed-release tablets are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see warnings; anaphylactic reactions, serious skin reactions) . - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or

Estats Units - anglès - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings; gastrointestinal bleeding, ulceration, and perforation) . diclofenac sodium delayed-release tablets, usp are indicated: diclofenac sodium delayed-release tablets are contraindicated in the following patients:

Malàisia - anglès - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

hovid berhad - potassium bicarbonate; sodium alginate -

Malàisia - anglès - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

hovid berhad - calcium carbonate; sodium bicarbonate; sodium alginate -

Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

reckitt benckiser (healthcare) sa-nv - sodium alginate 250 mg; calcium carbonate 80 mg; sodium hydrogen carbonate 133,5 mg - chewable tablet - 250 mg - sodium alginate 250 mg; sodium bicarbonate 133.5 mg; calcium carbonate 80 mg - alginic acid

Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

reckitt benckiser (healthcare) sa-nv - sodium hydrogen carbonate 106,5 mg; calcium carbonate 187,5 mg; sodium alginate 250 mg - chewable tablet - sodium bicarbonate 106.5 mg; sodium alginate 250 mg; calcium carbonate 187.5 mg - other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)

Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

reckitt benckiser (healthcare) sa-nv - sodium hydrogen carbonate 267 mg/10 ml; sodium alginate 500 mg/10 ml - oral suspension - sodium alginate 50 mg/ml; sodium bicarbonate 26.7 mg/ml - alginic acid

Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

reckitt benckiser (healthcare) sa-nv - sodium hydrogen carbonate 267 mg/10 ml; sodium alginate 500 mg/10 ml - oral suspension - 50mg/ml – 26,7mg/ml - sodium alginate 50 mg/ml; sodium bicarbonate 26.7 mg/ml - alginic acid